Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum

Neuroscience

Volumn 167, Issue 1, 2010, Pages 174-184

  Xu, G ^a   Xiong, Z ^a   Yong, Y ^b   Wang, Z ^a   Ke, Z ^b   Xia, Z ^a   Hu, Y ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Dopamine transporter (DAT); Glial cell derived neurotrophic factor (GDNF); MPP+ intoxication; MPTP chronic Parkinsonism model; Rotarod performance; Tyrosine hydroxylase (TH)

Indexed keywords

1 METHYL 4 PHENYLPYRIDIMIUM; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; CATALPOL; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; PROBENECID; PROTEIN TYROSINE KINASE INHIBITOR; REAGENT; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; BRAIN NERVE CELL; CATABOLISM; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG DOSE COMPARISON; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EXPERIMENTAL MODEL; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LOCOMOTION; MALE; MESENCEPHALON; MOUSE; NERVE CELL CULTURE; NERVE CELL DEGENERATION; NEURITE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; ROTAROD TEST; SUBSTANTIA NIGRA; UPREGULATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN; CELLS, CULTURED; CHRONIC DISEASE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLUCOSIDES; IRIDOIDS; MALE; MESENCEPHALON; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NERVE DEGENERATION; NEURAL PATHWAYS; NEURONS; NEUROPROTECTIVE AGENTS; PROBENECID; SUBSTANTIA NIGRA;

EID: 77950368837     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.01.048     Document Type: Article

References (59)

1. Afonso-Oramas D., Cruz-Muros I., de la Rosa D.A., Abreu P., Giráldez T., Castro-Hernández J., Salas-Hernández J., Lanciego J.L., Rodríguez M., González-Hernández T. Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease. Neurobiol Dis 2009, 36(3):494-508.
2. Bannon M.J. The dopamine transporter: role in neurotoxicity and human disease. Toxicol Appl Pharmacol 2005, 204:355-360.
3. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973, 20:415-455.
4. Bi J., Jiang B., Hao S., Zhang A.H., Dong Y.S., Jiang T., An L.J. Catalpol attenuates nitric oxide increase via ERK signaling pathways induced by rotenone in mesencephalic neurons. Neurochem Int 2009, 54:264-270.
5. 2-induced oxidative stress in astrocytes primary cultures. Neurosci Lett 2008, 442:224-227.
6. Brouard A., Pelaprat D., Dana C., Vial M., Lhiaubet A.M., Rostene W. Mesencephalic dopaminergic neurons in primary cultures express functional neurotensin receptors. J Neurosci 1992, 12:1409-1415.
7. Burt D.R., Enna S.J., Creese I., Snyder S.H. Dopamine receptor binding in the corpus striatum of mammalian brain. Proc Natl Acad Sci U S A 1975, 72:4655-4659.
8. Cass W.A., Peters L.E., Harned M.E., Seroogy K.B. Protective by GDNF and other trophic factors against the dopamine-depleting effects of neurotoxic doses of methamphetamine. Ann N Y Acad Sci 2006, 1074:272-281.
9. Dawson T.M., Dawson V.L. Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat Neruosci 2002, 5(Suppl):1058-1061.
10. Deierborg T., Soulet D., Roybon L., Hall V., Brundin P. Emerging restorative treatments for Parkinson's disease. Prog Neurobiol 2008, 85:407-432.
11. Deraerts M., Krylyshkina O., Debyser Z., Baekelandt V. Concise review: therapeutic strategies for Parkinson disease based on the modulation of adult neurogenesis. Stem Cells 2007, 25:263-270.
12. Dong A., Shen J., Krause M., Hackett S.F., Campochiaro P.A. Increased expression of glial cell line-derived neurotrophic factor protects against oxidative damage-induced retinal degeneration. J Neurochem 2007, 103:1041-1052.
13. Dunnett S.B., Björklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 1999, 399:A32-A39.
14. Encinas M., Tansey M.G., Tsui-Pierchala B.A., Comella J.X., Milbrandt J., Johnson E.M. c-Src is required for glial cell derived neurotrophic factor (GDNF) family ligand-mediated neuronal survival via a phosphatidylinositol-3 kinase (PI-3K)-dependent pathway. J Neurosci 2001, 21:1464-1472.
15. Evans J.R., Barker R.A. Neurotrophic factors as a therapeutic target for Parkinson's disease. Expert Opin Ther Targets 2008, 12:437-447.
16. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates 1997, 59-67. Academic Press, San Diego.
17. Günther I., Hall H., Halldin C., Swahn C.G., Farde L., Sedvall G. [125I] beta-CIT-FE and [125I] beta-CIT-FP are superior to [125I] beta-CIT for dopamine transporter visualization: autoradiographic evaluation in the human brain. Nucl Med Biol 1997, 24(7):629-634.
18. Himeda T., Kadoguchi N., Kamiyama Y., Kato H., Maegawa H., Araki T. Neuroprotective effect of arundic acid, an astrocyte-modulating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity. Neuropharmacology 2006, 50:329-344.
19. Hong M., Mukhida K., Mendez I. GDNF therapy for Parkinson's disease. Expert Rev Neurother 2008, 8(7):1125-1139.
20. Inoue T., Tsui J., Wong N., Wong S.Y., Suzuki F., Kwok Y.N. Expression of glial cell line-derived neurotrophic factor and its mRNA in the nigrostriatal pathway following MPTP treatment. Brain Res 1999, 826:306-308.
21. Ivanova T., Karolszak M., Beyer C. Estradiol stimulates GDNF expression in developing hypothalamic neurons. Endocrinology 2002, 143:3175-3178.
22. Ke Z.J., DeGiorgio L.A., Volpe B.T., Gibson G.E. Reversal of thiamine deficiency-induced neurodegeneration. J Neuropathol Exp Neurol 2003, 62:195-207.
23. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988, 318:876-880.
24. Knowles P.P., Murray-Rust J., Kjaer S., Scott R.P., Hanrahan S., Santoro M., Ibáñez C.F., McDonald N.Q. Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 2006, 281:33577-33587.
25. Kupsch A., Sautter J., Götz M.E., Breithaupt W., Schwarz J., Youdim M.B., Riederer P., Gerlach M., Oertel W.H. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm 2001, 108:985-1009.
26. Lamensdorf I., Youdim M.B., Finberg J.P. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem 1996, 67:1532-1539.
27. Ledda F., Paratcha G., Sandoval-Guzman T., Ibanez C.F. GDNF and GFRα1 promote formation of neuronal synapses by ligand-induced cell adhesion. Nat Neurosci 2007, 10(3):293-300.
28. Li D.Q., Bao Y.M., Bao J.J., Liu C.P., Liu Y., An L.J. Neuroprotective properties of catalpol in transient global cerebral ischemia in gerbils: dose-response, therapeutic time-window and long-term efficacy. Brain Res 2004, 1029:179-185.
29. Liang Y.Q., Tang X.C. Comparative studies of huperzine A, donepenzil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats. Acta Pharmacol Sin 2006, 27(9):1127-1136.
30. Liu Q.F., Xia Z.Q., Sun Q.X., Hu Y.E. Dual direction regulatory effect of catalpol on beta-adrenergic receptor and M-cholinergic receptor. J Shanghai Jiaotong Univ (Med Sci) 2007, 27:1432-1434.
31. Liu S., Hu Y.E., Xia Z.Q. Changes of memory and M receptor injection of A β25-35 into basal ganglion region of forebrain and effect of catalpol. J Shanghai Jiaotong Univ (Med Sci) 2007, 27:805-808.
32. Meredith G.E., Totterdell S., Patashkin J.A., Surmeier D.J. Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat Disord 2008, 14(Suppl 2):S112-S115.
33. Murer M.G., Yan Q., Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 2001, 63:71-124.
34. Nagatsu T., Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des 2005, 11:999-1016.
35. Nagatsu T., Sawada M. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm 2007, 72(Suppl):113-120.
36. Napolitano A., Bellini G., Borroni E., Zürcher G., Bonuccelli U. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats. Parkinsonism Relat Disord 2003, 9:145-150.
37. Nutt J.G., Carter J.H., Sexton G.J. The dopamine transporter: importance in Parkinson's disease. Ann Neurol 2004, 55:766-773.
38. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999, 22:123-144.
39. Oshio H., Inouye H. Iridoid glycosides of Rehmannia glutinosa. Phytochemistry 1981, 21:133-138.
40. Paveliev M., Airaksinen M.S., Saarma M. GDNF family ligands activate multiple events during axonal growth in mature sensory neurons. Mol Cell Neurosci 2004, 25:453-459.
41. Peterson A.L., Nutt J.G. Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 2008, 5:270-280.
42. Petroske E., Meredith G.E., Callen S., Totterdell S., Lau Y.S. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 2001, 106:589-601.
43. Potashkin J.A., Kang U.J., Loomis P.A., Jodelka F.M., Ding Y., Meredith G.E. MPTP administration in mice changes the ratio of splice isoforms of fosB and rgs9. Brain Res 2007, 28:1-10.
44. Price R.D., Miline S.A., Sharkey J., Matsuoka N. Advances in small molecules promoting neurotrophic function. Pharmacol Ther 2007, 115:292-306.
45. Rodad K., Rausch W.D., Gille G. Rotenone induces cell death in primary dopaminergic culture by increasing ROS production and inhibiting mitochondrial respiration. Neurochem Int 2006, 49:379-386.
46. Rozas G., Lopez-martin E., Guerra M.J., Labandeira-Garcia J.L. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods 1998, 83:165-175.
47. Saavedra A., Baltazar G., Duarte E.P. Interleukin-1beta mediates GDNF up-regulation upon dopaminergic injury in ventral midbrain cell cultures. Neurobiol Dis 2007, 25:92-104.
48. Salahpour A., Ramsey A.J., Medvedev I.O., Kile B., Sotnikova T.D., Holmstrand E., Ghisi V., Nicholls P.J., Wong L., Murphy K., Sesack S.R., Wightman R.M., Gainetdinov R.R., Caron M.G. Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter. Proc Natl Acad Sci U S A 2008, 105:4405-4410.
49. Savit J.M., Dawson V.L., Dawson T.M. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006, 116:1744-1754.
50. Schintu N., Frau L., Ibba M., Garau A., Carboni E., Carta A.R. Progressive dopaminergic degeneration in the chronic MPTP mouse model of Parkinson's disease. Neurotox Res 2009, 16(2):127-139.
51. Silverdale M.A., Fox S.H., Crossman A.R., Brotchie J.M. Potential nondopaminergic drugs for Parkinson's disease. Adv Neurol 2003, 91:273-291.
52. Sossi V., de la Fuente-Fernandez R., Schulzer M., Troiano A.R., Ruth T.J., Stoessl A.J. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol 2007, 62:468-475.
53. +-induced oxidative stress in mesencephalic neurons. Eur J Pharmacol 2007, 568:142-148.
54. + in mesensephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J 2008, 22:1-10.
55. Von Bohlen und Halbach O. Animal models of Parkinson's disease. Neurodegener Dis 2005, 2:313-320.
56. Wang J.H., Sun Q.X., Xia Z.Q., Hu Y.E. Regulatory effect of catalpol from Radix Rehmanniae on M2 receptor density in M2 receptor transfected CHO cells. Chin Pharmacol Bull 2006, 22:1462-1466.
57. Wang Z., Liu Q., Zhang R., Liu S., Xia Z., Hu Y. Catalpol ameliorates beta amyloid-induced degeneration of cholinergic neurons by elevating brain-derived neurotrophic factors. Neuroscience 2009, 163(4):1363-1372.
58. Yang X., Mertens B., Lehtonen E., Vercammen L., Bockstael O., Chtarto A., Levivier M., Brotchi J., Michotte Y., Baekelandt V., Sarre S., Tenenbaum L. Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model. J Gene Med 2009, 11(10):899-912.
59. +. FEBS Lett 2008, 582:956-960.